Department of General, Thoracic, Vascular and Transplantation Surgery, University of Rostock, Schillingallee 35, 18057, Rostock, Germany.
Department for General, Abdominal, Thoracic and Vascular Surgery, Katholisches Marienkrankenhaus Hamburg gGmbH, 22087, Hamburg, Germany.
Surg Endosc. 2017 Sep;31(9):3449-3458. doi: 10.1007/s00464-016-5404-x. Epub 2017 Jan 11.
Postoperative, iatrogenic or spontaneous upper gastrointestinal defects result in significant morbidity and mortality of the patients. In the last few years, endoscopic vacuum therapy (EVT) has been recognized as a new promising method for repairing upper gastrointestinal defects of different etiology. However, probably due to insufficient data and no commercially available system for EVT of the upper gastrointestinal tract, until the end of 2014, covering of esophageal defects with self-expanding metal stents (SEMS) were still the mainstay of endoscopic therapy. The aim of this article is to review the data available about EVT for various upper gastrointestinal defects.
A selective literature search was conducted in Medline and PubMed (2007-2016), taking into account all the published case series and case reports reporting on the use of EVT in the management of upper gastrointestinal defects.
EVT works through intracorporal application of negative pressure at the defect zone with an electronic controlled vacuum device along a polyurethane sponge drainage. This results in closure of the esophageal defect and internal drainage of the septic focus, simultaneously. Compared to stenting, EVT enables regular viewing of wound conditions with control of the septic focus and adjustment of therapy. Moreover, endoscopical negative pressure is applicable in all esophageal regions (cricopharygeal, tubular, gastroesophageal junction) and in anastomotic anatomic variants. EVT can be used solely as a definite treatment or as a complimentary therapy combined with operative revision. In total, there are published data of more than 200 patients with upper gastrointestinal defects treated with EVT, showing succes rates from 70-100%.
The available data indicate that EVT is feasible, safe and effective with good short-term and long-term clinical outcomes in the damage control of upper GI-tract leaks. Still, a prospective multi-center study has to be conducted to proof the definite benefit of EVT for patients with esophageal defects.
术后、医源性或自发性上消化道缺陷会导致患者出现显著的发病率和死亡率。在过去的几年中,内镜下真空治疗(EVT)已被认为是修复不同病因的上消化道缺陷的一种新的有前途的方法。然而,可能由于数据不足且没有用于上消化道 EVT 的商业可用系统,直到 2014 年底,自膨式金属支架(SEMS)覆盖食管缺损仍然是内镜治疗的主要方法。本文的目的是回顾有关 EVT 治疗各种上消化道缺陷的现有数据。
在 Medline 和 PubMed 中进行了选择性文献检索(2007-2016 年),考虑了所有发表的病例系列和病例报告,这些报告均报道了 EVT 在管理上消化道缺陷中的应用。
EVT 通过电子控制的真空装置在缺陷区域内应用腔内负压,沿着聚氨酯海绵引流管进行操作。这导致食管缺陷的闭合和感染灶的内部引流同时发生。与支架置入相比,EVT 能够通过控制感染灶和调整治疗来定期观察伤口情况。此外,内镜下负压适用于所有食管区域(环咽肌、管状、胃食管交界处)和吻合解剖变异。EVT 可以单独用作确定性治疗或与手术修正相结合的补充治疗。总共有 200 多名患有上消化道缺陷的患者接受了 EVT 治疗,其数据已发表,成功率为 70-100%。
现有数据表明,EVT 是可行的、安全的、有效的,对上消化道泄漏的损伤控制具有良好的短期和长期临床效果。然而,仍需要进行前瞻性多中心研究,以证明 EVT 对食管缺陷患者的明确益处。